Physician profile
Eui Kim
NPI 1063771202
$562.96
in general payments reported to CMS, 2019-2025
15 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.77 · 2023: $77.99 · 2024: $124 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417 · Honoraria: $58.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.19 |
| Honoraria | $58.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $125.00 | 2025 | Korlym |
| Axonics, INC. | $123.70 | 2024 | Axonics, Bulkamid |
| Becton, Dickinson and Company | $58.00 | 2025 | |
| Glaxosmithkline, LLC. | $45.38 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Biotech, INC. | $31.54 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $26.51 | 2025 | Opsumit |
| Astrazeneca Pharmaceuticals Lp | $24.90 | 2025 | Fasenra |
| Electromed, INC. | $20.70 | 2025 | Smartvest |
| Ardelyx, INC. | $19.07 | 2023 | Ibsrela |
| Insulet Corporation | $17.56 | 2023 | Omnipod |
| Novo Nordisk INC | $15.13 | 2022 | |
| Lilly USA, LLC | $15.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $14.92 | 2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $12.86 | 2022 | |
| Abbvie INC. | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eui Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.